retatrutide: The Triple Agonist That Could Redefine Metabolic Medicine (a full clinical breakdown from a clinical Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Patients should be asked about the use of other medications and medical conditions, which may exacerbate gastrointestinal symptoms and delay gastric emptying, such as, but not limited to bowel dysmotility, gastroparesis, and Parkinsons disease

The prominence of the frontal bone and the attachment of skin to the orbicularis oculi influence their appearance

EASO Secretariat (2022)

Ready to explore your weight loss options

Underdosing means you are paying for medication that cannot reach therapeutic levels

The TRIUMPH 4 study showed that patients with obesity and knee arthritis lost an average of almost 29% of their body weight - an average weight loss of 71 pounds